- Home
- STK vs TBPH Comparison
STK vs TBPH Comparison
Compare STK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- TBPH
- Stock Information
- Founded
- STK 2009
- TBPH 2013
- Country
- STK United States
- TBPH United States
- Employees
- STK N/A
- TBPH N/A
- Industry
- STK Investment Managers
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- TBPH Health Care
- Exchange
- STK Nasdaq
- TBPH Nasdaq
- Market Cap
- STK 434.6M
- TBPH 464.5M
- IPO Year
- STK N/A
- TBPH N/A
- Fundamental
- Price
- STK $28.42
- TBPH $9.90
- Analyst Decision
- STK
- TBPH Buy
- Analyst Count
- STK 0
- TBPH 3
- Target Price
- STK N/A
- TBPH $11.33
- AVG Volume (30 Days)
- STK 38.2K
- TBPH 241.0K
- Earning Date
- STK 01-01-0001
- TBPH 05-08-2025
- Dividend Yield
- STK 6.60%
- TBPH N/A
- EPS Growth
- STK N/A
- TBPH N/A
- EPS
- STK N/A
- TBPH N/A
- Revenue
- STK N/A
- TBPH $64,381,000.00
- Revenue This Year
- STK N/A
- TBPH $51.09
- Revenue Next Year
- STK N/A
- TBPH N/A
- P/E Ratio
- STK N/A
- TBPH N/A
- Revenue Growth
- STK N/A
- TBPH 12.12
- 52 Week Low
- STK $24.95
- TBPH $7.44
- 52 Week High
- STK $34.31
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- STK 57.66
- TBPH 58.86
- Support Level
- STK $27.85
- TBPH $9.90
- Resistance Level
- STK $28.29
- TBPH $10.55
- Average True Range (ATR)
- STK 0.53
- TBPH 0.36
- MACD
- STK 0.28
- TBPH 0.07
- Stochastic Oscillator
- STK 91.05
- TBPH 67.98
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).